title: Effect of comorbidities and medications on left ventricular mass regression after bariatric surgery.
abstract: Hypertension, diabetes, and obesity frequently coexist and significantly contribute to cardiovascular morbidity and mortality. Weight loss in obese individuals has been associated with improved blood pressure control and regression in left ventricular (LV) hypertrophy. The authors investigated the impact of comorbidity and medication on clinical and echocardiographic parameters after weight loss in obese patients. Serial echocardiography and clinical data were collected in 62 patients before bariatric surgery and after 6 months or 10% weight loss. Obese patients with diabetes or hypertension had higher baseline LV mass (LVM) (334 + or - 73 g in hypertension and diabetes vs 252 + or - 97 g in hypertension and 219 + or - 75 g in disease-free patients, P = .003; P = .089 for differences in LVM indexed by height), despite the lack of significant differences in body mass index or systolic blood pressure. There were no significant differences in baseline LVM or LVM index related to the medication used to treat hypertension. After weight loss, patients on beta-blocker therapy experienced the most significant LV hypertrophy regression (-76.5 + or - 79.1 g with beta-blockers, -17.8 + or - 43.7 g with diuretics, -4.5 + or - 46.6 g with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and -23.1 + or - 50.9 g in not treated patients, overall P = .538; beta-blockers vs no therapy P < .005; P = .145 for differences in LVM index). Bariatric surgery, combined with a weight loss program, provide substantial weight and LVM reduction regardless of comorbidities or blood pressure changes. beta-Blocker therapy appears to be associated with the greatest LVM regression after weight loss.
authors.affiliation: Department of Medicine, Internal Medicine, Albany Medical Center, Holy Rosary Medical Center, 1771 West Idaho Avenue, Ontario, OR 97914, USA. mmohsin7@yahoo.com
authors.forename: Mohsin
authors.initials: M
authors.lastname: Syed
authors.forename: Mikhail
authors.initials: M
authors.lastname: Torosoff
authors.forename: Carl
authors.initials: C
authors.lastname: Rosati
authors.forename: Sharon
authors.initials: S
authors.lastname: Alger
authors.forename: Steven
authors.initials: S
authors.lastname: Fein
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D050110:Bariatric Surgery; D001794:Blood Pressure / Q000187:drug effects; D015992:Body Mass Index; D002306:Cardiac Volume / Q000187:drug effects; D015897:Comorbidity; D004359:Drug Therapy, Combination; D004452:Echocardiography; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000453:epidemiology; D017379:Hypertrophy, Left Ventricular / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D011183:Postoperative Complications / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000453:epidemiology; D011446:Prospective Studies; D015431:Weight Loss
chemical_list: D000959:Antihypertensive Agents